OncoSec Medical Incorporated
Simbolis: ONCS
NASDAQ
0.2772
USDRinkos kaina šiandien
-0.0457
P/E santykis
-0.0010
PEG koeficientas
1.65M
MRK kapitalizacija
- 0.00%
DIV pajamingumas
OncoSec Medical Incorporated (ONCS) Finansinės ataskaitos
Balansas
common:word.in-mln USD Growth | TTM | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | |||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
balance-sheet.row.cash-and-short-term-investments | 41.19 | 12.3 | 46 | 20.4 | |||||||||||||||
balance-sheet.row.short-term-investments | 0 | 0 | 0 | 0 | |||||||||||||||
balance-sheet.row.net-receivables | 0 | 0 | 0 | 0 | |||||||||||||||
balance-sheet.row.inventory | 0 | 0 | 0 | 0 | |||||||||||||||
balance-sheet.row.other-current-assets | 10.25 | 2.9 | 3.2 | 2.5 | |||||||||||||||
balance-sheet.row.total-current-assets | 51.44 | 15.2 | 49.2 | 22.8 | |||||||||||||||
balance-sheet.row.property-plant-equipment-net | 17.97 | 5.6 | 6.4 | 6.8 | |||||||||||||||
balance-sheet.row.goodwill | 0 | 0 | 0 | 0 | |||||||||||||||
balance-sheet.row.intangible-assets | 1.48 | 0.4 | 0.4 | 0 | |||||||||||||||
balance-sheet.row.goodwill-and-intangible-assets | 1.48 | 0.4 | 0.4 | 0 | |||||||||||||||
balance-sheet.row.long-term-investments | 0 | 0 | 0 | 0 | |||||||||||||||
balance-sheet.row.tax-assets | 0 | 0 | 0 | 0 | |||||||||||||||
balance-sheet.row.other-non-current-assets | 2.29 | 0.6 | 0.3 | 0.3 | |||||||||||||||
balance-sheet.row.total-non-current-assets | 21.74 | 6.6 | 7.1 | 7.1 | |||||||||||||||
balance-sheet.row.other-assets | 0 | 0 | 0 | 0 | |||||||||||||||
balance-sheet.row.total-assets | 73.18 | 21.9 | 56.3 | 29.9 | |||||||||||||||
balance-sheet.row.account-payables | 0 | 0 | 0 | 0 | |||||||||||||||
balance-sheet.row.short-term-debt | 6.22 | 2 | 2.1 | 1.5 | |||||||||||||||
balance-sheet.row.tax-payables | 0 | 0 | 0 | 0 | |||||||||||||||
balance-sheet.row.long-term-debt-total | 14.19 | 4.1 | 5.2 | 6.4 | |||||||||||||||
Deferred Revenue Non Current | 0 | 0 | 0 | 0 | |||||||||||||||
balance-sheet.row.deferred-tax-liabilities-non-current | 0 | - | - | - | |||||||||||||||
balance-sheet.row.other-current-liab | 19.24 | 4.6 | 5.9 | 8.2 | |||||||||||||||
balance-sheet.row.total-non-current-liabilities | 34.19 | 9.1 | 10.2 | 6.4 | |||||||||||||||
balance-sheet.row.other-liabilities | 0 | 0 | 0 | 0 | |||||||||||||||
balance-sheet.row.capital-lease-obligations | 16.39 | 5.2 | 6.1 | 6.4 | |||||||||||||||
balance-sheet.row.total-liab | 59.65 | 15.8 | 18.2 | 16 | |||||||||||||||
balance-sheet.row.preferred-stock | 0 | 0 | 0 | 0 | |||||||||||||||
balance-sheet.row.common-stock | 0.01 | 0 | 0 | 0 | |||||||||||||||
balance-sheet.row.retained-earnings | -1158.6 | -286 | -251.8 | -206.6 | |||||||||||||||
balance-sheet.row.accumulated-other-comprehensive-income-loss | 1.48 | 0.2 | -0.1 | 0 | |||||||||||||||
balance-sheet.row.other-total-stockholders-equity | 1170.65 | 291.8 | 289.9 | 220.5 | |||||||||||||||
balance-sheet.row.total-stockholders-equity | 13.54 | 6.1 | 38.1 | 13.9 | |||||||||||||||
balance-sheet.row.total-liabilities-and-stockholders-equity | 73.18 | 21.9 | 56.3 | 29.9 | |||||||||||||||
balance-sheet.row.minority-interest | 0 | 0 | 0 | 0 | |||||||||||||||
balance-sheet.row.total-equity | 13.54 | 6.1 | 38.1 | 13.9 | |||||||||||||||
balance-sheet.row.total-liabilities-and-total-equity | 73.18 | - | - | - | |||||||||||||||
Total Investments | 0 | 0 | 0 | 0 | |||||||||||||||
balance-sheet.row.total-debt | 20.41 | 6.2 | 7.3 | 7.8 | |||||||||||||||
balance-sheet.row.net-debt | -20.78 | -6.1 | -38.6 | -12.5 |
Pinigų srautų ataskaita
common:word.in-mln USD Growth | TTM | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | |||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
cash-flows.row.net-income | -29.39 | -34.2 | -45.2 | -42.3 | |||||||||||||||
cash-flows.row.depreciation-and-amortization | 0.94 | 1.1 | 1.1 | 1 | |||||||||||||||
cash-flows.row.deferred-income-tax | 0 | 0 | -0.8 | -0.1 | |||||||||||||||
cash-flows.row.stock-based-compensation | 1.28 | 1.6 | 5.1 | 3.5 | |||||||||||||||
cash-flows.row.change-in-working-capital | 2.05 | -1.2 | -2.5 | 3.8 | |||||||||||||||
cash-flows.row.account-receivables | 0 | 0 | 0 | 0 | |||||||||||||||
cash-flows.row.inventory | 0 | 0 | 0 | 0 | |||||||||||||||
cash-flows.row.account-payables | -1.38 | -1.4 | -2.6 | 3.6 | |||||||||||||||
cash-flows.row.other-working-capital | 3.43 | 0.2 | 0.1 | 0.2 | |||||||||||||||
cash-flows.row.other-non-cash-items | 0.12 | 0.6 | 0.5 | 0.9 | |||||||||||||||
cash-flows.row.net-cash-provided-by-operating-activities | -24.99 | 0 | 0 | 0 | |||||||||||||||
cash-flows.row.investments-in-property-plant-an-equipment | -0.24 | -0.2 | -0.8 | 0 | |||||||||||||||
cash-flows.row.acquisitions-net | 0 | 0 | 0 | 0 | |||||||||||||||
cash-flows.row.purchases-of-investments | 0 | 0 | 0 | 0 | |||||||||||||||
cash-flows.row.sales-maturities-of-investments | 0 | 0 | 0 | 0 | |||||||||||||||
cash-flows.row.other-investing-activites | 0 | 0 | 0 | 0 | |||||||||||||||
cash-flows.row.net-cash-used-for-investing-activites | -0.26 | -0.2 | -0.8 | 0 | |||||||||||||||
cash-flows.row.debt-repayment | -1.15 | -1.3 | -0.6 | -0.1 | |||||||||||||||
cash-flows.row.common-stock-issued | 0.04 | 0 | 62.8 | 30 | |||||||||||||||
cash-flows.row.common-stock-repurchased | 0 | 0 | 0 | 0 | |||||||||||||||
cash-flows.row.dividends-paid | 0 | 0 | 0 | 0 | |||||||||||||||
cash-flows.row.other-financing-activites | 4.65 | 0.1 | 6 | -1.5 | |||||||||||||||
cash-flows.row.net-cash-used-provided-by-financing-activities | 3.54 | -1.2 | 68.2 | 28.4 | |||||||||||||||
cash-flows.row.effect-of-forex-changes-on-cash | -0.08 | -0.1 | 0 | 0 | |||||||||||||||
cash-flows.row.net-change-in-cash | -21.55 | -33.7 | 25.6 | -4.8 | |||||||||||||||
cash-flows.row.cash-at-end-of-period | 41.19 | 12.3 | 46 | 20.4 | |||||||||||||||
cash-flows.row.cash-at-beginning-of-period | 62.74 | 46 | 20.4 | 25.1 | |||||||||||||||
cash-flows.row.operating-cash-flow | -24.99 | -32.1 | -41.8 | -33.1 | |||||||||||||||
cash-flows.row.capital-expenditure | -0.24 | -0.2 | -0.8 | 0 | |||||||||||||||
cash-flows.row.free-cash-flow | -25.24 | -32.4 | -42.6 | -33.1 |
Pajamų ataskaitos eilutė
common:word.in-mln USD Growth | TTM | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | |||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
income-statement-row.row.total-revenue | 0 | 0 | 0 | 0 | |||||||||||||||
income-statement-row.row.cost-of-revenue | 0 | 0 | 0 | 0 | |||||||||||||||
income-statement-row.row.gross-profit | 0 | 0 | 0 | 0 | |||||||||||||||
income-statement-row.row.gross-profit-ratio | 0 | 0 | 0 | 0 | |||||||||||||||
income-statement-row.row.research-development | 21.77 | - | - | - | |||||||||||||||
income-statement-row.row.selling-general-administrative | 10.88 | - | - | - | |||||||||||||||
income-statement-row.row.selling-and-marketing-expenses | 0 | - | - | - | |||||||||||||||
income-statement-row.row.other-expenses | 0.06 | 0 | 0 | 0.2 | |||||||||||||||
income-statement-row.row.operating-expenses | 32.65 | 37 | 48.4 | 43.4 | |||||||||||||||
income-statement-row.row.cost-and-expenses | 32.65 | 37 | 48.4 | 43.4 | |||||||||||||||
income-statement-row.row.interest-income | 0 | 0 | 0 | 0 | |||||||||||||||
income-statement-row.row.interest-expense | 0.05 | 0 | 0 | 0 | |||||||||||||||
income-statement-row.row.selling-and-marketing-expenses | 0 | - | - | - | |||||||||||||||
income-statement-row.row.total-other-income-expensenet | -0.07 | -0.5 | 0.8 | 0.3 | |||||||||||||||
income-statement-row.row.ebitda-ratio-caps | 0 | - | - | - | |||||||||||||||
income-statement-row.row.other-operating-expenses | 0.06 | 0 | 0 | 0.2 | |||||||||||||||
income-statement-row.row.total-operating-expenses | -0.07 | -0.5 | 0.8 | 0.3 | |||||||||||||||
income-statement-row.row.interest-expense | 0.05 | 0 | 0 | 0 | |||||||||||||||
income-statement-row.row.depreciation-and-amortization | 0.99 | 1.1 | 1.1 | 1.2 | |||||||||||||||
income-statement-row.row.ebitda-caps | -31.66 | - | - | - | |||||||||||||||
income-statement-row.row.operating-income | -32.65 | -37 | -48.4 | -43.4 | |||||||||||||||
income-statement-row.row.income-before-tax | -32.72 | -37.5 | -47.6 | -43.1 | |||||||||||||||
income-statement-row.row.income-tax-expense | -2.58 | -3.3 | -2.4 | -0.9 | |||||||||||||||
income-statement-row.row.net-income | -30.14 | -34.2 | -45.2 | -42.3 |
Dažnai užduodami klausimai
Kas yra OncoSec Medical Incorporated (ONCS) bendras turtas?
OncoSec Medical Incorporated (ONCS) bendras turtas yra 21878368.000.
Kokios yra įmonės metinės pajamos?
Metinės pajamos yra N/A.
Kokia yra įmonės pelno marža?
Įmonės pelno marža yra 0.000.
Koks yra įmonės laisvųjų pinigų srautas?
Laisvųjų pinigų srautas yra -4.923.
Kokia yra įmonės grynojo pelno marža?
Grynojo pelno marža yra 0.000.
Kokios yra bendros įmonės pajamos?
Bendrosios pajamos yra 0.000.
Kas yra OncoSec Medical Incorporated (ONCS) grynasis pelnas (grynosios pajamos)?
Grynasis pelnas (grynosios pajamos) yra -34179634.000.
Kokia yra bendra įmonės skola?
Bendra skola yra 6174765.000.
Koks yra veiklos sąnaudų skaičius?
Veiklos sąnaudos yra 37012062.000.
Koks yra įmonės grynųjų pinigų skaičius?
Įmonės grynieji pinigai yra 3683330.000.